Genome & Company (KOSDAQ: A314130)
Health Care · Biotechnology · KR
₩5,470.00
-0.55% today · +93.6% 1Y
Genome & Company (KOSDAQ: A314130) operates in the Biotechnology industry within the Health Care sector. The company is valued at $212.80M.
Over the last twelve months the share price has gained 93.6%, trading between 2.58K and 10.18K.
Tweenvest scores Genome & Company across four factors: quality 58/100, value 76/100. Its strongest factor is value.
A314130 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $212.80M
- Revenue (TTM)
- $15.80M
- P/E
- —
- EPS
- -1,179.67
- Dividend yield
- —
- Beta (5Y)
- 0.28
- 52-week high
- ₩10,180.00
- 52-week low
- ₩2,585.00
- Avg volume (3M)
- —
- Shares outstanding
- 52.30M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Transgene SAENXTPA: TNG | $214.67M | €0.70 | -0.57% |
| Beijing Biostar Pharmaceuticals Co., Ltd.SEHK: 2563 | $213.47M | HK$4.30 | -10.97% |
| Cartesian Therapeutics, Inc.NasdaqGM: RNAC | $213.45M | $6.99 | -0.92% |
| Lyell Immunopharma, Inc.NasdaqGS: LYEL | $213.44M | $8.27 | -5.05% |
| Invivyd, Inc.NasdaqGM: IVVD | $212.58M | $0.67 | -6.64% |
| Guangzhou Innogen Pharmaceutical Group Co., LtdSEHK: 2591 | $209.56M | HK$3.60 | -3.49% |
| HLB Therapeutics Co.,Ltd.KOSDAQ: A115450 | $208.16M | ₩3,175.00 | +28.54% |
| TaiGen Biopharmaceuticals Holdings LimitedTPEX: 4157 | $207.71M | NT$9.33 | +7.86% |
Figures last refreshed Oct 11, 2026.